Welcome to our dedicated page for LENSAR SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENSAR, Inc. filings document operating results and material events for a commercial-stage medical device company focused on robotic laser systems for cataract procedures. Form 8-K reports furnish quarterly and annual earnings releases, including disclosures on ALLY system activity, installed-base trends, and recurring revenue components such as procedure, lease, and service revenue.
The company’s filings also record capital and governance matters, including common stock listed on Nasdaq under LNSR, officer transition disclosures, and material agreements such as the Priority Credit Line Agreement. Amendments to material-event reports provide additional detail on credit-line terms, collateral arrangements, interest-rate mechanics, and default provisions.
Winer Gary M reported acquisition or exercise transactions in this Form 4 filing.
LENSAR, Inc. director Gary M. Winer received an equity award of 17,421 restricted stock units, each representing one share of common stock. These RSUs vest in full on June 3, 2027, subject to his continued service, and bring his direct holdings to 105,635 shares. The award was granted as part of the company’s non-employee director compensation program and will be settled upon vesting or earlier upon certain events such as a change in control, death, disability, or termination of service.
LINDSTROM RICHARD L MD reported acquisition or exercise transactions in this Form 4 filing.
LENSAR, Inc. reported that director Richard L. Lindstrom, MD received a grant of 17,421 restricted stock units (RSUs) of common stock as part of his annual non-employee director compensation. Each RSU represents one share of common stock and was granted at no cash purchase price.
The RSUs vest in full on June 3, 2027, if he continues to provide service to the company through that date. They will be settled in shares upon the earliest of his service termination, a change in control of the company, or his death or disability. Following this award, he holds 263,831 shares directly.
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
LENSAR, Inc. director William J. Link, Ph.D. received a grant of 17,421 restricted stock units (RSUs) of common stock on June 3, 2026 as part of his annual non-employee director compensation. Each RSU represents a contingent right to one share of common stock and will vest in full on June 3, 2027, if he continues serving the company through that date. The RSUs will be settled in shares upon the earliest of his termination of service, a change in control of the company, or his death or disability. Following this grant, his direct holdings reported in this filing total 568,062 shares and RSUs.
LENSAR, Inc. filed an initial Form 3 for Michael A. Rossi, who serves as Interim CFO. This filing is a required disclosure when an executive becomes a reporting insider under SEC rules. The data provided show no reported transactions or holdings in this Form 3, so it functions purely as an initial registration of Mr. Rossi’s insider status with no share purchases, sales, or option exercises disclosed.
LENSAR, Inc. appointed Michael A. Rossi as Interim Chief Financial Officer and principal financial officer, effective May 29, 2026. Rossi, 52, has extensive healthcare and life sciences finance experience, including prior CFO roles at Access Vascular, ConcertAI and Harvard Bioscience.
The company entered a consulting agreement with Monomoy Advisors LLC, under which Monomoy makes Rossi available at a cash retainer of $375 per hour. LENSAR also set its 2026 virtual annual meeting for August 4, 2026, with holders of common stock and Series A Convertible Preferred Stock of record as of June 10, 2026 entitled to vote. Stockholder proposal and director nomination notices, including those under universal proxy rules, must be received by the company by the close of business on June 8, 2026.
Brandes Investment Partners amended a Schedule 13G to report beneficial ownership of 1,026,018 common shares of LENSAR, Inc., representing 8.48% of the class as of 09/30/2025. The amendment lists shared voting power of 937,207 shares and shared dispositive power of 1,026,018 shares. The filing is signed by Executive Director Glenn Carlson on 05/07/2026.
LENSAR, Inc. director and Chief Executive Officer Nicholas T. Curtis reported an administrative change in his share record related to vested restricted stock units. Mr. Curtis paid cash to cover associated tax withholding, so no shares were transferred and his direct holdings remained at 992,096 shares of common stock.
LENSAR, Inc. Chief Operating Officer Alan B. Connaughton reported a routine tax-related share disposition. On May 6, 2026, 2,739 shares of common stock were withheld by the company at $5.385 per share to cover tax obligations from vesting restricted stock units. After this non‑market transaction, he directly holds 354,330 shares of LENSAR common stock.
LENSAR, Inc. Chief Financial Officer Thomas R. Staab II reported a routine tax-related share disposition. On May 6, 2026, 1,350 shares of common stock were withheld at $5.385 per share to cover tax obligations triggered by vesting of restricted stock units. After this withholding, he holds 174,609 shares of LENSAR common stock directly. This was not an open-market sale but an automatic tax-withholding transaction.